modelPanitumumab

Diagram of Panitumumab

Extends from Pharmacolibrary.Drugs.ATC.L.L01FE02.

Information

name:Panitumumab
ATC code:L01FE02
route:intravenous
compartments:2
dosage:600mg
volume of distribution:3.83L
clearance:0.273L/day
other parameters in model implementation

Panitumumab is a fully human monoclonal antibody targeting the epidermal growth factor receptor (EGFR). It is primarily used for the treatment of metastatic colorectal cancer, especially in patients with wild-type KRAS status. It is approved for medical use and is administered via intravenous infusion.

Pharmacokinetics

Pharmacokinetic parameters reported in adult cancer patients (metastatic colorectal cancer), generally similar across sexes. Values are based on population pharmacokinetic analyses.

References

  1. Doi, T, et al., & Ohtsu, T (2009). Safety and pharmacokinetics of panitumumab in Japanese patients with advanced solid tumors. International journal of clinical oncology 14(4) 307–314. DOI:10.1007/s10147-008-0855-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19705240

  2. Krens, LL, et al., & Gelderblom, H (2014). Pharmacokinetics of panitumumab in a patient with liver dysfunction: a case report. Cancer chemotherapy and pharmacology 73(2) 429–433. DOI:10.1007/s00280-013-2353-0 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24258455

  3. Yang, BB, et al., & Pérez Ruixo, JJ (2010). Pharmacokinetic and pharmacodynamic perspectives on the clinical drug development of panitumumab. Clinical pharmacokinetics 49(11) 729–740. DOI:10.2165/11535970-000000000-00000 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20923247

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)